Is biotech billionaire Kirk's Intrexon worth $1.4B?

Intrexon has set terms for a proposed $125 million IPO that could value the company at $1.4 billion, providing one of the latest indications of bullish evaluations for the biotech startups going public this year. Germantown, MD-based Intrexon, a synthetic biology outfit led by billionaire Randal Kirk, aims to sell 8.3 million shares at a proposed range of $14 to $16 per share. At the midpoint of that range, Kirk's startup would be worth $1.4 billion and more than the $1.2 billion Forest Labs ($FRX) paid for his previous company Clinical Data after it won FDA approval for an antidepressant in 2011. Intrexon has spread its bets across a variety of industries and players inside and outside of the pharma world, yet the company may never become profitable, like many other companies going public this year. In 2012 the company, a 2011 Fierce 15 winner, had a net loss of $103 million on revenue of $14 million. Kirk, who has already invested a fortune in the company, has also made a nonbinding pledge to invest up to $30 million in the IPO. If the deal goes through, we will find out the company's market value. S-1/A | More | Fierce 15 profile

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.